New Alzheimer's drug met with hope and caution

New Alzheimer's drug met with hope and caution

  • Af
  • Episode
      1113
  • Published
      1. dec. 2022
  • Forlag
0 Anmeldelser

0

Episode

1113 of 1969

Længde

24M

Sprog

Engelsk

Format

Kategori

Fakta

Two pharmaceutical companies, Eisai and Biogen, have published the results of an 18-month human trial for their new drug, lecanemab. It's meant to treat people with early stages of Alzheimer's disease, a devastating condition that causes the majority of dementia cases and affects hundreds of thousands of Canadians.

The results of the lecanemab trial are promising — the condition of people who were given the drug declined at a rate that was 27 per cent slower than those who were given a placebo. It's a glimmer of hope for those facing Alzheimer's disease, but questions about the new drug remain.

Today, Mike Crawley, a reporter with CBC's health unit, is here to explain how the drug works and what it may mean for people living with Alzheimer's disease.


Lyt når som helst, hvor som helst

Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis

    Lyt og læs så meget du har lyst til

    Opdag et kæmpe bibliotek fyldt med fortællinger

    Eksklusive titler + Mofibo Originals

    Opsig når som helst

Prøv nu
DK - Details page - Device banner - 894x1036
Cover for New Alzheimer's drug met with hope and caution

Other podcasts you might like ...

Læs mere

    Om Mofibo

    Jobs

    nye app-funktioner

    Investor Relations

    Presse

    Bæredygtighed

    Tilgængelighedserklæring

    Whistleblow

Udforsk

    Søg

    Bøger

    Bogserier

    Mofibo Originals

    Podcasts

    Forfattere

    Indlæsere

    Kategorier

Brugbare links

    Hjælpecenter

    Abonnementer

    Køb gavekort

    Indløs gavekort

    Indløs kampagnekode

    Studierabat


Sprog og region
  • Dansk

  • Danmark

  • app_store_button
  • google_play_button
Følg os

    Privatlivspolitik

    Medlemsvilkår

    Cookies